BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/26/2024 1:28:46 PM | Browse: 317 | Download: 1023
 |
Received |
|
2023-09-27 07:51 |
|
Peer-Review Started |
|
2023-09-27 07:53 |
|
First Decision by Editorial Office Director |
|
2023-12-04 19:48 |
|
Return for Revision |
|
2023-12-04 19:48 |
|
Revised |
|
2023-12-18 15:25 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-01-25 03:03 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-01-25 05:04 |
|
Articles in Press |
|
2024-01-25 05:04 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-02-20 00:53 |
|
Publish the Manuscript Online |
|
2024-02-26 13:28 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong-Xiao Wu, Xiao-Yan Ding, Ya-Wen Xu, Ming-Hua Yu, Xiao-Mi Li, Na Deng and Jing-Long Chen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jing-Long Chen, Doctor, Chief Doctor, Cancer Center, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. cjl6412@ccmu.edu.cn |
| Key Words |
Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Lenvatinib; PD-1 inhibitor; Portal vein tumor thrombus |
| Core Tip |
Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) has a poor prognosis and treatment responses. Assessment of its survival has important clinical implications. Through our research, we discovered that a triplet regimen of PD-1 inhibitor/TACE/Lenvatinib was safe and well-tolerated as well as exhibited favorable efficacy over the TACE/Lenvatinib regimen for advanced-stage HCC comorbid with PVTT. |
| Publish Date |
2024-02-26 13:28 |
| Citation |
Wu HX, Ding XY, Xu YW, Yu MH, Li XM, Deng N, Chen JL. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2024; 30(8): 843-854
|
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i8/843.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i8.843 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
